HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Warnke, D. Articles by Temesgen, Z. Search for Related Content PubMed PubMed Citation Articles by Warnke, D. Articles by Temesgen, Z. Social Bookmarking                   What's this?

Antiretroviral Drugs

From the Mayo Clinic and Foundation, Rochester, Minnesota.

The first antiretroviral drug to be licensed, zidovudine, became available in 1987. Until December 1995, the antiretroviral drugs available and approved for clinical use in the United States consisted of only 5 individual drugs belonging to a single class of antiretroviral agents, nucleoside analog reverse transcriptase inhibitors. Since then, numerous other antiretroviral drugs and classes of antiretroviral drugs have been introduced. Additional drugs and newer classes of antiretrovirals are in various stages of development. Currently, there are 22 Food and Drug Administration (FDA)-approved antiretroviral agents categorized in 4 classes of drugs: nucleoside/nucleotide analog reverse transcriptase inhibitors, nonnucleoside analog reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors. The authors review the general characteristics of each class of antiretroviral drugs, including mechanism of action, pharmacologic properties, adverse effects, and drug interactions. A synopsis of current antiretroviral treatment guidelines is also provided.

Key Words: antiretrovirals • HIV • nucleoside analog reverse transcriptase inhibitors • nonnucleoside reverse transcriptase inhibitors • protease inhibitors • fusion inhibitors

Address for correspondence: Zelalem Temesgen, MD, AAHIVS, Mayo Clinic and Foundation, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905; e-mail: temesgen.zelalem{at}mayo.edu.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Giri, S. Agarwal, N. Shaik, G. Pan, Y. Chen, and W. F. Elmquist Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design Drug Metab. Dispos., March 1, 2009; 37(3): 560 - 570. [Abstract] [Full Text] [PDF]